Biopharma Business

Early-phase contract research organisation Richmond Pharmacology has opened its new research facility in London Bridge, at the site formerly known as the Guy’s Drug Research Unit.

The organisation state that the new facility will provide a central London base in which further research, utilising enhanced capabilities in delivering early-phase clinical trials, can be conducted. Richmond Pharmacology has already conducted over 300 studies in London since its establishment in 2001.

Dr Jorg Taubel, CEO of Richmond Pharmacology said: “The opening of our new research facility, at what was formerly known as the Guy’s Drug Research Unit, is an exciting addition to our research capability, and will help us to provide the best possible support for our clients in their drive to increase the effectiveness and cost efficiency of developing new drugs and taking them to market.The new facility will enable Richmond to apply the most up to date research techniques for ground-breaking research projects and crucially, at scale – something we think will be highly attractive to our clients in the UK and around the world.”

Sarah Haywood, chief executive officer of the London collaborative life science effort, Med City UK, said: “Clinical trials are an essential part of the process to bring new healthcare products to patients. London and the UK offers an ideal location for clinical studies. London with 8.3 million NHS patients, a third of which were born overseas, provides an excellent platform for clinical research organisations like Richmond Pharmacology.”